The Indian Journal of Pediatrics

, Volume 86, Issue 2, pp 111–112 | Cite as

Congenital Adrenal Hyperplasia and Growth Outcomes

  • Rajni SharmaEmail author
Editorial Commentary

Congenital adrenal hyperplasia (CAH) is a disorder of adrenal gland cortisol biosynthesis caused by key enzyme deficiencies, the most common being 21-hydroxylase in 90–95% cases [1]. Depending on the severity, there are two forms of CAH: classical (a severe enzymatic deficiency with onset in the neonatal period, infancy or childhood) and non-classical (a milder form manifesting in later life). Classical forms are further classified into salt-wasting (SW) (associated with mineralocorticoid deficiency and adrenal crisis) and simple-virilizing (SV) (normal/subclinical mineralocorticoid deficiency) types. The lack of cortisol stimulates pituitary adreno corticotropic hormone (ACTH) release that leads to adrenal hyperplasia and accumulation of cortisol precursors like 17-hydroxyprogesterone (17-OHP), which are shunted to the alternate metabolic pathway of androgen synthesis. High levels of androgens and testosterone manifest as genital virilization in girls and pseudo-precocious puberty in...


Compliance with Ethical Standards

Conflict of Interest


Source of Funding



  1. 1.
    Bonfig W. Growth and development in children with classic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2017;24:39–42.Google Scholar
  2. 2.
    Sharma R, Seth A. Congenital adrenal hyperplasia: issues in diagnosis and treatment in children. Indian J Pediatr. 2014;81:178–85.CrossRefGoogle Scholar
  3. 3.
    Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society Clinical Practice. J Clin Endocrinol Metab. 2018;103:4043–88.Google Scholar
  4. 4.
    Muthusamy K, Elamin MB, Smushkin G, et al. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2010;95:4161–72.CrossRefGoogle Scholar
  5. 5.
    Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2003;88:5680–8.CrossRefGoogle Scholar
  6. 6.
    Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classicalcongenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab. 2009;94:3882–8.CrossRefGoogle Scholar
  7. 7.
    Maheshwari A, Khadilkar V, Gangodkar P, Khadilkar A. Long-term growth in congenital adrenal hyperplasia. Indian J Pediatr. 2018.
  8. 8.
    Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain 665 normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85:1114–20.CrossRefGoogle Scholar
  9. 9.
    Verma S, Vanryzin C, Sinaii N, et al. A pharmacokinetic and pharmacodynamic study of delayed and extended-release hydrocortisone (Chronocort) vs. conventional 671 hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol. 2010;72:441–7.CrossRefGoogle Scholar
  10. 10.
    Lin-Su K, Harbison MD, Lekarev O, Vogiatzi MG, New MI. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J Clin Endocrinol Metab. 2011;96:1710–7.CrossRefGoogle Scholar
  11. 11.
    Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics. 2000;106:767–73.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  1. 1.Division of Pediatric Endocrinology, Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations